Depression and cognition scores revealed significantly less worsening in the rasagiline group compared with the placebo group ( differences in Movement Disorder Society-sponsored revision of the Unified Parkinson 's Disease Rating Scale item-adjusted means [ SEs ] , -0.19 [ 0.10 ] , P = .048 , and -0.20 [ 0.05 ] , P < .001 , respectively ) .